MRVI vs RGEN
MRVI: Maravai LifeSciences provides essential nucleic acid synthesis reagents and bioprocessing analytical tools that underpin the development and manufacturing of next-generation vaccines and therapies. RGEN: Repligen provides critical bioprocessing technologies and consumables that enable the efficient manufacturing of biological medicines and advanced therapies.
Side-by-side fundamentals
| Metric | MRVI | RGEN | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $7.21 | $163.84 | |
| Market cap | $1.9B | $9.2B | |
| P/E as of 2026-10-08 | n/a | 223.31 | |
| Net margin FY2025, SEC XBRL | -70.4% | n/a | |
| Gross margin FY2025, SEC XBRL | +18.3% | n/a | |
| Operating margin FY2025, SEC XBRL | -115.9% | n/a | |
| ROE FY2025, SEC XBRL | -35.1% | +2.3% | RGEN higher |
| ROA FY2025, SEC XBRL | -17.0% | +1.7% | RGEN higher |
| Debt / equity as of 2026-09-03 | 0.86 | 0.26 | RGEN lower |
| Revenue growth (YoY) as of 2026-09-03 | -3.3% | +16.5% | RGEN higher |
| Revenue CAGR (3y) SEC XBRL | -40.5% | +30.5% | RGEN higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.38 | 1.38 | |
| 1-year return as of 2026-10-08 close | +116.5% | +8.6% | MRVI higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.